About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Tg(tetO-Esr1)#Paf
transgene insertion, Priscilla A Furth
MGI:5296756
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Trp53tm1Brd/Trp53+ 		involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB MGI:5297135
cx2
 		Tg(MMTVtTA)1Mam/0
Tg(tetO-Esr1)#Paf/0 		involves: C57BL/6 * FVB/N * SJL MGI:5296757
cx3
 		Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0 		involves: FVB/N MGI:5296806


Genotype
MGI:5297135
cn1
Allelic
Composition		 Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Trp53tm1Brd/Trp53+
Genetic
Background		 involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm2Cxd mutation (3 available); any Brca1 mutation (114 available)
Tg(MMTV-cre)4Mam mutation (1 available)
Tg(MMTV-rtTA)1Lach mutation (0 available)
Tg(tetO-Esr1)#Paf mutation (0 available)
Trp53tm1Brd mutation (5 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
endocrine/exocrine glands
mammary gland alveolar hyperplasia ( J:132088 )
• mutants develop hyperplastic alveolar nodules
increased mammary gland tumor incidence ( J:132088 )
• 100% of mutants develop invasive mammary cancer
• some cancers are Esr1-negative while others are Esr1-positive

neoplasm
increased mammary gland tumor incidence ( J:132088 )
• 100% of mutants develop invasive mammary cancer
• some cancers are Esr1-negative while others are Esr1-positive
preneoplasia ( J:132088 )
• mutants develop mammary gland preneoplasia
• some preneoplasia are Esr1-negative while others are Esr1-positive

integument
mammary gland alveolar hyperplasia ( J:132088 )
• mutants develop hyperplastic alveolar nodules
increased mammary gland tumor incidence ( J:132088 )
• 100% of mutants develop invasive mammary cancer
• some cancers are Esr1-negative while others are Esr1-positive

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
hereditary breast ovarian cancer syndrome DOID:5683 J:132088




Genotype
MGI:5296757
cx2
Allelic
Composition		 Tg(MMTVtTA)1Mam/0
Tg(tetO-Esr1)#Paf/0
Genetic
Background		 involves: C57BL/6 * FVB/N * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(MMTVtTA)1Mam mutation (3 available)
Tg(tetO-Esr1)#Paf mutation (0 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
endocrine/exocrine glands
abnormal seminal vesicle morphology ( J:78639 )
• when 14 week old males are removed from doxycycline administration for 50 days, seminal vesicles show a decrease in mass compared to controls

reproductive system
abnormal seminal vesicle morphology ( J:78639 )
• when 14 week old males are removed from doxycycline administration for 50 days, seminal vesicles show a decrease in mass compared to controls
decreased epididymis weight ( J:78639 )
• when 14 week old males are removed from doxycycline administration for 50 days, epididymis weight is decreased compared to controls
abnormal vas deferens morphology ( J:78639 )
• when 14 week old males are removed from doxycycline administration for 50 days, vas deferens weight is decreased compared to controls
short estrus ( J:78639 )
• females raised on doxycycline to block expression of Esr1 exhibit a decrease in the number of days in estrus when the doxycycline is removed and Esr1 is expressed, however overall cycle length is no different from controls
decreased litter size ( J:78639 )
• mutants without doxycycline (expressing Esr1) exhibit a 15% reduction in litter size compared to mutants receiving doxycycline




Genotype
MGI:5296806
cx3
Allelic
Composition		 Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Genetic
Background		 involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
endocrine/exocrine glands
abnormal mammary gland morphology ( J:96383 )
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development
abnormal mammary gland epithelium morphology ( J:96383 )
• rates of mammary epithelial cell proliferation are increased compared to controls
abnormal mammary gland duct morphology ( J:96383 )
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching
abnormal branching of the mammary ductal tree ( J:96383 )
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts
mammary gland duct hyperplasia ( J:96383 )
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia
abnormal mammary gland lobule morphology ( J:96383 )
• 52% of mutants at 4 months of age show lobular hyperplasia
mammary gland alveolar hyperplasia ( J:96383 )
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias
increased mammary gland ductal carcinoma incidence ( J:96383 )
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

neoplasm
increased mammary gland ductal carcinoma incidence ( J:96383 )
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

integument
abnormal mammary gland morphology ( J:96383 )
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development
abnormal mammary gland epithelium morphology ( J:96383 )
• rates of mammary epithelial cell proliferation are increased compared to controls
abnormal mammary gland duct morphology ( J:96383 )
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching
abnormal branching of the mammary ductal tree ( J:96383 )
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts
mammary gland duct hyperplasia ( J:96383 )
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia
abnormal mammary gland lobule morphology ( J:96383 )
• 52% of mutants at 4 months of age show lobular hyperplasia
mammary gland alveolar hyperplasia ( J:96383 )
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias
increased mammary gland ductal carcinoma incidence ( J:96383 )
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
 J:96383




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory